Merck & Co., Inc., Rahway, N.J., USA Announces Second-Quarter 2025 Financial Results

About this update from Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class A

[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":217,"url":"https://media.zenfs.com/en/business-wire.com/81795535fca143ac9b3b5e1ea786e494"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/6qSnwkbNRwPY0bXbrzX1CA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQzNDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/81795535fca143ac9b3b5e1ea786e494","width":480,"height":217}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Total Worldwide Sales Were $15.8 Billion, a Decrease of 2% From Second Quarter 2024 Both Nominally and Excluding the Impact of Foreign Exchange","length":143,"tagName":"p","attribs":{}},{"type":"list","items":[{"val":[{"type":"text","content":"KEYTRUDA Sales Were $8.0 Billion, Growth of 9% Both Nominally and Excluding the Impact of Foreign Exchange","length":106,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"WINREVAIR Sales Were $336 Million","length":33,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Animal Health Sales Were $1.6 Billion, Growth of 11% Both Nominally and Excluding the Impact of Foreign Exchange","length":112,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"GARDASIL/GARDASIL 9 Sales Were $1.1 Billion, a Decline of 55% Both Nominally and Excluding the Impact of Foreign Exchange","length":121,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":372,"olType":false}]},{"val":[{"type":"text","content":"GAAP EPS Was $1.76; Non-GAAP EPS Was $2.13; GAAP and Non-GAAP EPS Include a Charge of $0.07 per Share for Closing of Hengrui Pharma License Agreement","length":149,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Announced Agreement To Acquire Verona Pharma and Its First-In-Class COPD Maintenance Treatment for Adults, Ohtuvayre®;1 Transaction Expected To Close in Fourth Quarter 2025","length":172,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Announced Positive Topline Results From First Two Phase 3 CORALreef Trials of Enlicitide Decanoate for Treatment of Adults With Hyperlipidemia","length":142,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Received FDA Approval of ENFLONSIA for Prevention of RSV Lower Respiratory Tract Disease in Infants Born During or Entering Their Firs...

More updates from Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class A